Innate Pharma S.A. Innate Pharma S.A.

Innate Pharma S.A.

IPHA

Rank in Stocks #19445
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery,... Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
Share Price
$1.03
Last synced: 2026-11-18
Market Cap
$101.84M
Change (1 day)
-22.56%
Change (1 year)
-43.41%
Country

Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this

Category

Healthcare
Dividend yield history for Innate Pharma S.A. (IPHA)
Innate Pharma S.A. (stock symbol: IPHA) dividend yield (TTM) as of 2025: 0.00%
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Innate Pharma S.A. (IPHA) from 2005 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
2026 (TTM) 0.00% 0.00%
2025 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% -100.00%
2014 0.21% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% -100.00%
2009 1.89% 0.00%
2008 0.00% 0.00%
2007 0.00% 0.00%
2006 0.00% 0.00%
2005 0.00% 0.00%
Dividend yields (TTM) for similar companies or competitors

Questions about Innate Pharma S.A.'s dividend yield

What was Innate Pharma S.A.'s dividend yield in 2025?

In 2025, Innate Pharma S.A.'s dividend yield was 0.00%, compared with 0.00% in 2024.

How has Innate Pharma S.A.'s dividend yield changed since 2020?

From 2020 to 2025, Innate Pharma S.A.'s dividend yield was highest in 2025 (0.00%) and lowest in 2025 (0.00%).

How does Innate Pharma S.A.'s dividend yield compare with similar companies?

Innate Pharma S.A.'s dividend yield (0.00%) is lower than that of all 5 similar companies listed above. The highest among them is CSL Limited, with 2.00%.